# A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

Study · id `cardio:ct-nct04657003` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04657003](<https://clinicaltrials.gov/study/NCT04657003>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04657003

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 938 participants.

## Technical summary

Registry record NCT04657003. Randomized; double masking; primary purpose treatment. Start 2021-03-29 (actual); primary completion 2023-03-16 (actual). Results posted on 2024-04-08.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 938 participants (enrolled count; ClinicalTrials.gov record NCT04657003, source copy `cardio:ctgov-nct04657003-2024-04-08`, retrieved 2026-10-26)
- Started: 2021-03-29 (actual) (ClinicalTrials.gov record NCT04657003, source copy `cardio:ctgov-nct04657003-2024-04-08`, retrieved 2026-10-26)
- Primary completion: 2023-03-16 (actual) (ClinicalTrials.gov record NCT04657003, source copy `cardio:ctgov-nct04657003-2024-04-08`, retrieved 2026-10-26)
- Completion: 2023-04-10 (actual) (ClinicalTrials.gov record NCT04657003, source copy `cardio:ctgov-nct04657003-2024-04-08`, retrieved 2026-10-26)
- Results first posted: 2024-04-08 (ClinicalTrials.gov record NCT04657003, source copy `cardio:ctgov-nct04657003-2024-04-08`, retrieved 2026-10-26)
- Countries: United States; Argentina; Brazil; India; Japan; Puerto Rico; Russia; Taiwan (ClinicalTrials.gov record NCT04657003, source copy `cardio:ctgov-nct04657003-2024-04-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04657003-2024-04-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
- Acronym: SURMOUNT-2
- Condition: Type 2 Diabetes
- Condition: Overweight
- Condition: Obesity
- Intervention (Drug): Tirzepatide
- Intervention (Other): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (`cardio:pubmed-37385275`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6a05a442120aa743c37d774c2b9408673ea2f225c965364400ef1241d92209de
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
